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Abstract: A large number of assays designed for genotyping human papillomaviruses (HPV) have been developed in the 
last years. They perform within a wide range of analytical sensitivity and specificity values for the different viral types, 
and are used either for diagnosis, epidemiological studies, evaluation of vaccines and implementing and monitoring of 
vaccination programs. Methods for specific genotyping of HPV-16 and HPV-18 are also useful for the prevention of 
cervical cancer in screening programs. Some commercial tests are, in addition, fully or partially automated. Automation of 
HPV genotyping presents advantages such as the simplicity of the testing procedure for the operator, the ability to process 
a large number of samples in a short time, and the reduction of human errors from manual operations, allowing a better 
quality assurance and a reduction of cost. The present review collects information about the current HPV genotyping tests, 
with special attention to practical aspects influencing their use in clinical laboratories. 
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INTRODUCTION 
 The establishment of a persistent infection by some of the 
several high-risk human papillomavirus (HR-HPV) is a 
necessary step in the development of cervical carcinoma [1-
3]. HPV infection is frequent in sexually active people, but 
the persistent infection develops only in a small proportion 
of cases. HPV persistency involves a risk of developing 
precancerous cervix lesions and, eventually, cervical cancer 
[4-6]. Among the HPVs from the genus alpha (those 
infecting the mucosal epithelium), 10 to 15 genotypes have 
been qualified as HR-HPV on the basis of their association 
with cancer [7-10]. The World Health Organization (WHO) 
International Agency for Research on Cancer (IARC) 
include, however, at present only twelve of them (HPV-16,  
-18, -31, -33, -45, -51, -52, -56, -58 and -59) into such 
consideration [7], the types 66 and 68 being excluded from 
their last classifications. However, these two types were 
present in the widespread classifications previously 
published, and most commercial tests for HR-HPV detection 
have included both into the design [8-10]. HR-HPV 
genotypes 16 and 18 are the most clinically relevant, since 
they are involved in about 70% of cases of cervical cancer 
[8, 11, 12]. 
 HPVs cannot be cultured in vitro by conventional 
methods, and the wide natural variation of the humoral 
immune response after the infection impairs the use of HPV-
specific antibody testing in diagnosis [13]. Diagnosis of the  
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HPV infection is, therefore, achieved by molecular testing, 
mainly by detection of genomic HPV DNA. 
 Several practice guidelines for cervical screening have 
proposed in the last years the use of HR-HPV detection 
adjunctively with cervical cytology to screen women aged 30 
and older and to determine the need for referral to 
colposcopy of women with ASCUS (atypical squamous cells 
of undetermined significance) cervical cytology results [14, 
15]. Also, the genotype specific identification of HPV-16 
and HPV-18 in women with a positive HR-HPV test and 
negative cytological results has been recommended [16]. 
 Two HR-HPV DNA-based screening tests have the US 
Food and Drug Administration (FDA) approval: in April 
2003, Hybrid Capture 2 (HC2) High-Risk DNA Test 
(Qiagen, Gaithersburg, MD, USA) and in April 2009, 
Cervista
TM
 HPV HR, (Hologic, Inc, Marlborough, MA, 
USA). Both techniques detect concurrently 13 HPV 
genotypes (HPV-16, -18, -31, -33, -45, -51, -52, -56, -58, -59 
and -68); Cervista
TM
 HPV HR test further includes HPV-66. 
HC2 is an in vitro nucleic acid hybridization assay with 
signal-amplification and Cervista is based on the Invader 
Chemistry
®
, which detects specific nucleic acid sequences 
using two isothermal reactions simultaneously. Other 
commercially available tests for pooled detection of HR-
HPV genotypes are Amplicor HPV test (Roche Molecular 
Systems, Inc, Pleasanton, CA, USA), based on PCR 
amplification and Care HPV Test (Qiagen) based on hybrid 
capture technology detecting the same 13 HPV types 
included in HC2 plus HPV-66. 
 Given the clinical relevance of HPV-16 and HPV-18, 
some HPV screening assays include the specific 
identification of these types, and are collectively referred to 
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as HR-HPV DNA-based screening assays with concurrent or 
reflex HPV-16 and HPV-18 genotyping. 
CHARACTERISTICS OF COMMERCIAL TESTS 
FOR HR-HPV GENOTYPING 
 HPV genotyping tests are used in studies of HPV-type 
specific prevalence among the population, in the evaluation 
of vaccines, and in the implementation and monitoring of 
vaccination programs. Specific HPV-16 and HPV-18 
identification is, in addition, recommended for screening 
programs, as mentioned above. Since a proper quality 
assurance is required in all cases, the WHO HPV Laboratory 
Network (LabNet) agreed and implemented international 
proficiency studies for monitoring the performance of assays 
for HPV DNA detection and typing [17, 18]. Approval of 
any of these assays for clinical use is achieved only after 
careful consideration of the results obtained in validation 
studies, which can eventually record an acceptable 
performance in terms of sensitivity and specificity for 
detecting clinically relevant disease (CIN 2) [19]. 
 A large number of assays for HPV genotyping have been 
developed in the last years, and some of them have been 
commercialised and introduced in clinical and research 
laboratories. Full or partial automation is offered by some 
assays. The analytical sensitivities of theses assays for each 
HPV type have been shown very diverse [20-22]. Several 
studies have been published comparing HR-HPV-DNA 
based screening with concurrent and reflex HPV-16 and 
HPV-18 genotyping and DNA based genotyping assays in 
the last years [23-26]. Relevant issues such as the sample 
size, the population studied, the procedure used for specimen 
collection, or the method used for DNA extraction must be 
taken into account for an appropriate comparison of the 
results obtained in these studies. 
 The performance of automated methods for HPV 
genotyping is an issue of special interest, since automation 
simplifies the testing procedure, increases the sample 
processing capability, minimises the human errors, facilitates 
the quality assurance and reduces the cost. In addition, 
screening tests with reflex or concurrent HPV-16 and HPV-
18 identification are also of consideration. 
 Table 1 shows a list of the main assays for HPV 
genotyping or HPV-16 and HPV-18 identification currently 
available. The technologies used by these tests include 
hybrid capture, Invader
®
 chemistry, real time PCR, PCR-
reverse hybridisation and PCR-microarray. 
HR-HPV Screening Methods with Reflex or Concurrent 
HPV-16 and HPV-18 Identification 
 Four HR-HPV screening methods with reflex or concur-
rent HPV-16 and HPV-18 identification are commerc-ialised 
at present, two of them under the US FDA approval: Cobas 
HPV (Roche Molecular Systems) and Cervista HPV-16/18 
(Hologic). The other two are the RealTime High Risk HPV 
test (Abbott Molecular, Des Plaines, IL, USA) and the HR-
HPV 16/18/45 Probe Set Test (Qiagen). 
Cobas 4800 HPV Test (Roche Molecular Systems) 
 Cobas 4800 HPV is a multiplex assay based on the real 
time PCR technology, intended to identify HPV-16 and 
HPV-18 with concurrent detection of twelve other HPV 
types (HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59,  
-66, -68). It achieved the US FDA approval in April 2011 for 
use in women aged 30 years and over, or women aged 21 
years and older with borderline cellular cytology results, in 
order to evaluate the need of performing additional 
diagnostic procedures or follow-up. The PCR amplification 
is achieved with specific primers and probes for the 14 HPV 
types and for the endogenous human gene for beta globin, 
used for assessing sample celularity, DNA extraction and 
absence of PCR inhibitors (internal control). Four different 
fluorescent dyes are used for the detection of the PCR 
products: one for the beta globin gene, one for HPV-16, one 
for HPV-18 and one for the remaining twelve HPV types. 
Samples collected in Cobas
®
 PCR Cell Collection Media 







 Preservative Fluid (not approved in 
the US) (BD Diagnostics, Burlington, NC, USA) are valid 
for use in this assay. The analytical sensitivity reported by the 
manufacturer is genotype dependent and ranges from 80 to 
2,400 copies of the target per ml of sample. 
 The test is fully automated by the Cobas system, which is 
composed of two different instruments: the Cobas x 480 
instrument, for the extraction of DNA and the preparation of 
the PCR mixture; and the Cobas z 480 analyzer, which 
performs the PCR reaction. Recording and interpretation of 
results is done by the Cobas 4800 System software. 
 The Cobas 4800 system can process up to 280 samples in 
one day and can be connected to a laboratory network 
system. The only manual step that the operator should 
perform is the loading of the PCR microwell plate in the 
Cobas z 480 analyzer. 
Cervista HPV 16/18 Test (Hologic) 
 This test uses the patented Invader  chemistry and the 
Invader Reporter
TM
 software to detect HPV-16 and HPV-18 
DNA, and enjoys the US FDA approval since 2009 with two 
indications: Identification of HPV-16 and HPV-18 in women 
aged 30 and over (adjunctively with Cervista
TM
 HPV HR and 
in combination with cervical cytology) and in women with 





 Solution (Hologic) are valid for this 
assay. The analytical sensitivity reported by the 
manufacturer ranges from 625 to 1,250 copies per reaction 
for both types. 
 The assay can be performed either manually or fully 
automated using the Sample Tranfer System (STS) 
(Thinprep 5000) and the Medium Throughput Automation 
(MTA) (Cervista). The STS automatically transfers the 
samples to the 96 well microplate and allows the processing 
of 96 samples in two hours. The MTA platform performs 
automatically DNA extraction, preparation of the Cervista 
test, incubation, detection, and analysis of results. The 
processing capability of the automated procedure is 24, 48 or 
96 samples per run. 
RealTime High Risk HPV Test (Abbott Molecular) 
 The Abbott RealTime High Risk (HR) HPV test is an 
assay based on the real time PCR technology that achieves 
pooled detection of twelve HR-HPV genotypes (HPV-31,  
-33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68) with 
concurrent HPV-16 and HPV-18 detection. Amplification is 
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performed using five different primers (designed in the L1 
HPV genomic region) and single stranded DNA probes. 
Endogenous human beta globin gene fragment detection is 





 Solution (Hologic), Surephath (BD 
Diagnostics) or Abbott Cervi-Collect (Abbott Molecular) can 
be tested by this assay. The analytical sensitivity reported by 
the manufacturer is 500 copies per assay for HPV types -16, 
-18, -35, -39, -45, -51, -59, -66 and -68; 2,000 copies per 
assay for HPV types -31, -33, -52 and -56; and 5,000 copies 
per assay for HPV-58. 
 Testing is performed automatically by the Abbott 
Systems m24sp or m2000sp for DNA extraction, and by the 
Abbott m2000rt device for amplification, detection and 
analysis of results, with hands-on time less than 15 minutes. 
The processing capability is 24, 48 or 96 samples per run. 
The total processing time for each run depends on the 
number of samples tested, because of the variable time 
consumed by DNA extraction and reagent preparation. 
Ninety-six samples can be tested in less than six hours using 
m2000sp in combination with m2000rt. 
 
 
HR-HPV 16/18/45 Probe Set Test (Qiagen) 
 HR-HPV 16/18/45 Probe Set Test is a signal 
amplification assay based on the hybrid capture technology 
using a probe mix comprising short sequence-specific 
synthetic probes designed for HPV-16, -18 and -45 
detection. The analytical sensitivity of the assay is 5,000 
copies per reaction. 
 The sample processing is the same as that for the HC2 
test, where DNA-RNA hybrids are captured in a solid phase 
(microtiter well) and are detected by specific antibodies 
conjugated with alkaline phosphatase, which generate 
quimioluminiscence once the substrate is added. The test 
performs like the HC2 test for the three HPV types targeted 
[27], and the manual steps are kept to a minimum using the 
Rapid Capture  System (RCS), since hybridisation, capture 
and signal amplification steps are achieved automatically. 
The processing capability of the automated procedure is 352 
samples per run. 
HPV Genotyping Tests 
 Several methods for HPV genotyping are at present 
available for testing clinical samples and five of the most 
Table 1. Characteristics and Analytical Sensitivity of the Main HR-HPV Screening Assays with Reflex or Concurrent HPV-16 and 
HPV-18 Genotyping and HPV Genotyping Assays 
 
HPV Assay Technology Automation Analytical Sensitivity 
HR-HPV screening assays with HPV-16/18 genotyping  
Cobas 4800 HPV Test 
(Roche Molecular Systems) */** 
Real time PCR 
Fully automated high-throughput 
(COBAS 4800) 
80-2,400 copies/ml 




(Cervista Medium throughput automation - MTA) 
625-1,250 copies/reaction 
RealTime High Risk HPV test (Abbott 
Molecular)* 
Real time PCR 
Fully automated high-throughput  
(m2000sp + m2000rt)  
500-5,000 copies/assay  




(Rapid Capture System-RCS) 
5,000 copies/assay 
HPV genotyping assays  












 DNA extraction 
 Hybridization/Detection 
50-8,000 copies/ml 
PapilloCheck HPV-Screening Test 
(Greiner Bio-One) * 
PCR-microarray 
Partially automated 
 DNA extraction 
 Interpretation 
30-750 copies/reaction 
Clart HPV 2 (Genomica) * PCR-microarray 
Partially automated 
 DNA extraction: 
 Detection/Interpretation 
10-100 copies/reaction 
Infiniti HPV Genotyping assay 
(AutoGenomics) * 
PCR-microarray 




*Conformité Européenne (CE marked); **U.S Food and Drug Administration approval. 
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frequently used can be partially automated. Table 2 shows 
the HPV genotypes identified by them: 
INNO-LiPA HPV Genotyping Extra (Innogenetics, Gent, 
Belgium) 
 This test is based on reverse line blot hybridisation, and 
was designed for the identification of 28 different HPV 
genotypes: 17 HR and probably carcinogenic HPV types 
(HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, -53, -56, 
-58, -59, -66, -68 and -82); seven low risk (LR)-HPV types 
(HPV-6, -11, -40, -43, -44, -54 and -70); and four HPV types 
of unknown oncogenic risk (HPV-69, -71, -73 and -74) [7]. 
Amplification of the human major histocompatibility 
complex, class II, DP beta 1 (HLA-DPB1) gene is used to 
monitor the sample quality and the efficiency of the DNA 
extraction. 
 The assay has been validated for samples collected in 
Surepath
®
 medium (BD Diagnostics). The DNA extraction is 
not part of the INNO-LiPA HPV Genotyping Extra, and the 
manufacturer recommends proteinase K treatment as the 
method of choice. Standard protocols for cervical cell 





Solution (Hologic), combined with HPV DNA extraction by 
commercially available kits, can be used, but require in-
house validation. Automatic DNA extractors as Magnapure 
(Roche Molecular Systems), BioRobot M48 or EZ1 
workstation (Qiagen), or m2000sp (Abbott Molecular) allow 
partial automation. 
 The limit of detection ranges between 20 and 70 copies 
per reaction depending on the genotype tested. Genotype 
inclusivity testing showed that all genotypes were detected 
with a threshold limit of 1,000 copies per PCR reaction 
except for HPV-59, which required 10,000 copies. 
 Hybridisation of the amplified PCR products with HPV-
specific probes immobilized in the strip can be performed 
automatically by the Auto-LIPA 48 device (Innogenetics), 
which achieves also the detection step. The interpretation of 
results can also be automated using LIRAS for LIPA HPV 
software. 
Linear Array HPV Genotyping Test (Roche Molecular 
Systems) 
 The Linear Array HPV Genotyping Test is an assay 
based on reverse line blot hybridisation registered in the 
European Union for the detection of 37 HPV genotypes, 
including HPV-6, -11, -16, -18, -26, -31, -33, -35, -39, -40,  
-42, -45, -51, -52, -53, -54, -55, -56, -58, -59, -61, -62, -64,  
-66, -67, -68, -69, -70, -71, -72, -73 (MM9), -81, -82 (MM4), 
-83 (MM7), -84 (MM8), IS39, and CP6108. 
 A pool of primers designed in the HPV L1 genomic 
region are used for PCR amplification. Amplification of an 
endogenous human beta globin gene sequence is used as 
internal control. The test has been validated for use in 
cervical samples collected in Cobas
®
 PCR Cell Collection 






 The limit of detection reported by the manufacturer for 
18 of the 37 HPV genotypes detected (HPV-6, -16, -18, -26, 
-31, -33, -35, -39, -45, -51, -53, -56, -58, -59, -66, -68, -73 
and -82) ranges from 53 to 8,089 copies per ml of sample. 
 The method recommended by the manufactured for DNA 
extraction, Amplilute Liquid Media Extraction Kit (Roche 
Molecular Systems), is a manual method, but the step can be 
performed by other methods after in-house validation. 
Automatic DNA extractors as Magnapure (Roche Molecular 
Systems), BioRobot M48 or EZ1 workstation (Qiagen), 
m2000sp (Abbott Molecular) allow partial automation. As 
for the INNO-LiPA HPV Genotyping Extra, the 
hybridisation and detection steps can be automated using 
Auto-LIPA 48 (Innogenetics) and ProfiBlot
TM
 T48 (Tecan 
Group, Mannedorf, Switzerland). 
PapilloCheck  Test Kit (Greiner Bio-One GmbH, 
Frickenhausen, Germany) 
 PapilloCheck  Test Kit is a PCR-based microarray assay 
intended to use for the qualitative detection and 
identification of 24 HPV genotypes in DNA preparations 
from cervical smears. The method detects 16 HR or probably 
carcinogenic HPV types (HPV-16, -18, -31, -33, -35, -39,  
-45, -51, -52, -53, -56, -58, -59, -66, -68 and -82), seven LR-
HPV types (HPV-6, -11, -40, -42, -43, -44 and -70), and two 
types of uncertain oncogenic risk (HPV-55 and HPV-73) [7]. 
HPV types -44 and -55 are detected simultaneously and 
cannot be discriminated. 
 Amplification of a fragment of the E1 HPV gene with 
specific primers is followed by hybridisation with specific 
DNA probes fixed on Papillocheck  DNA chip. Scanning of 
the chip is performed by the CheckScanner
TM
 device. 
Amplification and detection of a human Adenosine 
deaminase tRNA-specific 1 (ADAT1) gene sequence is 
included as internal control. DNA extracted from cervical 
smears collected in PapilloCheck
 
collection medium, 





(Hologic) is suitable for testing. 
 The limit of detection of the assay ranges from 30 to 750 
copies per reaction and depends on the genotype. 
 Only DNA extraction and interpretation of results can be 
automated. BioRobot M48 or EZ1 workstation (Qiagen), 
using MagAttractDNAMini M48 Kit and EZ1 DNA Tissue 
Kit, respectively, or NucliSENS easyMAG (bioMérieux 
Marcy l'Etoile, France) can be used for DNA extraction, as 
declared by the manufacturer. The CheckReport
TM
 software 
records the scanning of the chip and performs the evaluation 
and analysis of results. 
Clart  Papillomavirus Humano 2 (Genomica, Madrid, 
Spain) 
 Clart  Papillomavirus Humano 2 is a PCR-based 
microarray assay which detects 35 HPV types, 17 HR or 
probably carcinogenic HPV types (HPV-16, -18, -26, -31,  
-33, -35, -39, -45, -51, -52, -53, -56, -58, -59, -66, -68 and  
-82), twelve LR-HPV types (HPV-6, -11, -40, -42, -43, -44,  
-54, -61, -70, -72, -81 and -89), and six of undetermined 
oncogenic risk HPV types (HPV-62, -71, -73, -83, -84 and  
-85) [7]. The amplification of a 450 pb fragment of the L1 
HPV gene is followed by the detection using the low density 
microarray technology CLART
®
 (Clinical Array 
Technology). Amplification of a sequence from the cystic 
fibrosis transmembrane conductance regulator (CFRT) 
human gene is used as internal control. Testing can be 
performed on samples collected with swabs and ThinPrep
® 
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PreservCyt
®
 Solution (Hologic). Analytical sensitivity 
ranges from 10 to 100 copies, depending of the genotype. 
 DNA extraction can be performed automatically by 
NucliSENS easyMAG (bioMérieux) and BioSprint 96 
(Qiagen), which were both validated for use in this test. 
Recording and interpretation of results can also be automated 
by the Clinical Array Reader (CAR) and the Clinical Array 
Processor (CAP) (Genomica). 
Infiniti HPV Genotyping Assay (AutoGenomics Inc, 
California, USA) 
 There are three different Infiniti HPV genotyping assays 
for research use, all of them based in PCR–microarray. 
Automatic hybridization and detection of a 300 bp fragment 
amplified from the HPV E1 gene is achieved on fill-based 
microarrays (BioFilmChip). Infiniti HPV QUAD identifies 
13 HPV types individually (HPV-16, -18, -31, -33, -45) or in 
Table 2. HPV Genotypes Detected by HR-HPV Screening Tests with Reflex or Concurrent HPV-16 and HPV-18 Genotyping and 




 HPV TYPES 
HR/Probably Carcinogenic 16 18 26 31 33 35 39 45 51 52 53 56 58 59 66 68 82 
Cobas 4800 HPV Test  X X  X X X X X X X  X X X X X  
Cervista HPV 16/18 Test X X                
RealTime High Risk HPV test X X  X X X X X X X  X X X X X  
HR-HPV 16/18/45 Probe Set Test X X      X          
INNO-LiPA HPV Genotyping Extra X X X X X X X X X X X X X X X X X 
Linear Array HPV Genotyping Test X X X X X X X X X X X X X X X X X 
PapilloCheck  Test Kit X X  X X X X X X X X X X X X X X 
Clart  Papillomavirus Humano 2 X X X X X X X X X X X X X X X X X 
Infiniti HPV QUAD X X  X X X X X X X  X X X  X  
Infiniti HR-HPV QUAD X X  X X X X X X X  X X X X X  
Infiniti HPV genotyping X X X X X X X X X X X X X X X X X 
LR 6 11 13 40 42 43 44 54 61 70 72 81 89     
Cobas 4800 HPV Test                   
Cervista HPV 16/18 Test                  
RealTime High Risk HPV test                  
HR-HPV 16/18/45 Probe Set Test                  
INNO-LiPA HPV Genotyping Extra X X  X  X X X  X        
Linear Array HPV Genotyping Test X X  X X   X X X X X      
PapilloCheck  Test Kit X X  X X X X   X        
Clart  Papillomavirus Humano 2 X X  X X X X X X X X X X     
Infiniti HPV QUAD X X                
Infiniti HR-HPV QUAD                  
Infiniti HPV genotyping X X        X        
Undetermined Risk 30 34 55 62 64 67 69 71 73 74 83 84 85     
Cobas 4800 HPV Test                   
Cervista HPV 16/18 Test                  
RealTime High Risk HPV test                  
HR-HPV 16/18/45 Probe Set Test                  
INNO-LiPA HPV Genotyping Extra       X X X X        
Linear Array HPV Genotyping Test   X X X X X X X  X X      
PapilloCheck  Test Kit   X      X         
Clart  Papillomavirus Humano 2    X    X X  X X X     
Infiniti HPV QUAD                  
Infiniti HR-HPV QUAD                  
Infiniti HPV genotyping X X    X X  X    X     
aOncogenic risk classification of HPV genotypes was establish according to 2009 IARC Monograph Working Group [7]. 
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combination (-35/-68, -39/-56, -58/-52, -59/-51), as well as 
two LR-HPV types pooled (HPV-6/-11). Infiniti HR-HPV 
QUAD detects 14 HR or probably carcinogenic HPV types 
(HPV-16, -18, -31, -33, -39, -45, -51, -52, -56, -58, -59, -66 
and -68). Finally, Infiniti HPV Genotyping identifies 26 
HPV types: 17 HR or probably carcinogenic HPV types 
(HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, -53, -56, 
-58, -59, -66, -68 and -82), three LR-HPV types (HPV-6, -11 
and -70), and six of undetermined oncogenic risk (HPV-30,  
-34, -67, -69, -73 and -85). Endogenous human beta globin 
gene fragment amplification is used as internal control. 
Analytical sensitivity reported for Infiniti tests ranges from 
300 copies per reaction for HPV-16 to 3,000 copies for 
HPV-18 [28]. 
 Samples collected in Surepath
®





 Solution (Hologic) 
have been validated for use in these tests. Assays perform 
fully automated using the Infiniti
TM
 Analyser, a multiplexing 
microarray platform. 
AUTHORS’ RECOMMENDATIONS 
• Currently, a wide variety of commercial HPV 
genotyping methods exist. Selection of the more 
appropriate one depends on the intended use, i.e.: 
epidemiology, vaccine evaluation, or clinical studies. 
 For epidemiological studies, HPV genotyping 
methods allow drawing of type specific prevalence. 
 For vaccine evaluation, these assays provide data in 
regard to changes in prevalence for HPV types not 
included in the current vaccines, and facilitate the 
follow up of persistent infections. 
 For clinical studies, the current international 
guidelines recommend the use of HPV genotyping 
tests among women 30 years and older with 
negative cytology and a HR HPV positive results, in 
special HPV-16 and HPV-18. Identification of less-
carcinogenic HPV types would be of minor interest. 
• HPV genotyping methods displaying high analytical 
sensitivity are especially suitable for epidemiological 
studies, for evaluating vaccine efficacy and for 
detecting multiple HPV infections. Methods of lesser 
analytical sensitivity increase the positive predictive 
value in screening programs for cervical cancer, and 
are suitable in follow-up of treated patients. 
• Even commercial methods already validated by the 
manufacturers must be performed with strict 
standardisation and with observation of quality 
assurance criteria. Clinical validation is an absolute 
requirement for using any test in clinical studies. 
• Fully automated methods detecting HR HPV types 
pooled with concurrent or reflex HPV-16 and  
HPV-18 genotyping may present advantages for 
routine clinical practice. 
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